At Northshore–Edward Elmhurst Health, all patients are offered genetic testing as part of their primary care visit. This helps clinicians create more personalized care plans and facilitates earlier disease diagnoses, said Kristen Murtos, the health system's chief innovation and transformation officer.
By continuing an open discussion on precision medicine and precision care, we can truly accelerate pharmacogenomic testing to its full potential and focus on providing the highest quality care to those who need it most.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Optimizing drug routines allows prescribers to make more informed decisions that reduce risk and improve quality of care. The result is better outcomes for both patients and organizations.
Nest Genomics just closed a $8.5 million seed financing round. The company provides the software infrastructure needed for health systems, clinics, drugmakers and payers to launch and scale genomic programs. It also provides tools for patients to easily access their genetic information.
Without the help of genomics specialists, it is hard for health plans to manage genomic benefits efficiently and effectively. Now is the time for health plans to evaluate their genomic benefits management programs to find the right expert guidance and utilization management support.
In a recent interview, Jennifer Cubino, COO of BC Platforms, discussed regulatory differences between the U.S., the European Union and other countries amid ongoing efforts to encourage patients who want to share their data.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Illumina Accelerator has invested in 68 companies so far, all of them startups developing genomics technologies. Seven startups comprise the latest cohort selected by the startup engine.
All the hype around precision medicine can make it seem intimidating and foreign. The good news is that it does not represent a departure from current clinical practice, and it can significantly improve patient care.
Learn how healthcare organizations are working with Microsoft to enhance patient engagement, accelerate healthcare innovation, support collaboration, improve clinical and operational insights and transform healthcare in the cloud.
Bionano Genomics is acquiring genomics software firm BioDiscovery in a $90 million cash and stock deal. While both companies provide genomics analysis solutions, Bionano said combining its technology with BioDiscovery’s software will provide the integrated offering that many labs want.
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
Combining the two companies would allow patients to access genetic testing and their health records in one place, and make it easier for Invitae to collect and organize health records.
With a goal of making precision medicine the standard of care at health systems, Sema4 struck a nearly $800 million deal with CM Life Sciences to go public. The company, which offers tools that combine genomic and clinical data to glean patient care insights, will get $500 million in cash proceeds to grow its business.
The INVEST Precision Medicine conference cast a spotlight on the role of children's hospitals, biopharma companies, diagnostic companies and startups in biopharma innovation. The video recordings of the conference sessions are now available to view.
Read new developments from Serimmune, Allelica, ForSight Robotics, Owlet Baby Care Inc., and Ascension Ventures.
Read about news from Seven Bridges, Outcomes4Me, Carrum Health and more.